PARIS--(BUSINESS WIRE)--Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D ...

CAMBRIDGE, Mass., and PARIS--(BUSINESS WIRE)-- EOS imaging (www.eos-imaging.com) announced today that it has received FDA clearance of its sterEOS 3D orthopedic imaging workstation for use in lower ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. EOS Imaging recently announced a new online service ...

PARIS--(BUSINESS WIRE)--Regulatory News: EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D ...

Low-Dose 2D/3D Orthopedic Imaging System Adopted by Leading U.S. Hospital CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)-- EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic ...

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)-- EOS imaging (www.eos-imaging.com) announced today that it is retiring the corporate name ‘biospace med’ and will now officially be known as ‘EOS imaging’, ...

PARIS, May 12, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq: ATEC) and EOS IMAGING, S.A. are pleased to report strong progress in the tender offer filed by ATEC for the common shares and ...

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings announcement EOS imaging SA's (EPA:EOSI) released ...

Please provide your email address to receive an email when new articles are posted on . EOS Imaging announced the receipt of a CE Mark for its hipEOS, a 3-D hip arthroplasty planning software based on ...

Ongoing Impacts of COVID-19 Pandemic Constitute “Material Adverse Effect” Company Intends to Explore Other Strategic Collaborations with EOS Terminates Debt Commitment of up to $160 Million to Finance ...

1.1 The evidence indicated insufficient patient benefit in terms of radiation dose reduction and increased throughput to justify its cost. No evidence was identified on patient benefits from the EOS ...